摘要
鼻咽癌(NPC)的治疗已步入到了调强放射治疗(IMRT)时代,患者的治愈率及其生存质量(QOL)明显得到了提高,并且其不良反应也明显减轻。早期NPC的首选是放射治疗,但临床Ⅱ期NPC能否受益于放化疗综合治疗,目前尚有争议。另外,亚组分析发现,提高T2N1M0期患者的预后是临床Ⅱ期鼻咽癌研究进展中的瓶颈。
The treatment of nasopharyngeal carcinoma has entered in the era of intensity modulated radiation therapy(IMRT),which improved cure rate and quality of life and reduced adverse effects significantly. Radiation therapy has become the standard treatment for early stage nasopharyngeal carcinoma,however,controversy still exists regarding whether stage Ⅱ patients can benefit from the combination of radiotherapy with chemotherapy. Besides,subgroup analyses have found that to improve the prognosis of patients in T2 N1 M0 stage is the key problem for research of stage Ⅱ nasopharyngeal carcinoma.
作者
吴鹏
杨玲麟
WU Peng,YANG Ling-lin(The Affiliated Hospital of Southwest Medical University,Luzhou 646000,Chin)
出处
《中国肿瘤》
CAS
CSCD
北大核心
2018年第5期353-358,共6页
China Cancer
基金
国家自然科学基金青年科学基金项目(81201784)
关键词
鼻咽癌
调强放疗
化疗
亚组分析
nasopharyngeal carcinoma
intensity modulated radiation therapy(IMRT)
chemotherapy
subgroup analysis